Investigator Debarment Checks: What Sponsors Must Verify Before a Trial Starts
The FDA has the power to debar individuals from providing services to companies that submit abbreviated new drug applications and certain other applications. If a sponsor runs a clinical trial with a debarred investigator, the consequences can be severe. The data from that site may be rejected, the marketing application may stall, and the sponsor may face enforcement action. A simple screening step prevents all of it.
The Clarity Clinical Solutions training module on investigator debarment checks walks through why these checks exist, how to perform them, and what to do when a possible match appears. The core message: no study should ever start without completing this verification.
What debarment actually is
Debarment is a legal action that bars an individual from providing services in any capacity to a generic drug applicant or certain other FDA-regulated entities. The authority comes from the Generic Drug Enforcement Act of 1992, codified in sections 306 and 307 of the Federal Food, Drug, and Cosmetic Act. Debarred individuals cannot conduct or supervise clinical studies intended for submission to the FDA.
Debarment can be mandatory, for felony convictions related to drug development, or permissive, at the FDA's discretion for lesser offenses. The FDA maintains the list publicly, with names, debarment dates, and the legal basis for each action (FDA Debarment List (Drug Product Applications)).
Conducting a trial with a debarred investigator can lead to the FDA refusing to accept data from that site, which can compromise the entire study. It may also trigger warning letters, clinical holds, or disqualification proceedings. Beyond the regulatory risk, there is legal liability and reputational damage. Debarment applies to individuals, not organizations, so checks have to cover people by name.
Who gets checked
The check must cover every clinical investigator and sub-investigator on the study: the principal investigator, all sub-investigators, and anyone else making significant contributions to the conduct of the trial. Some sponsors extend the check to key site staff such as study coordinators and regulatory personnel. Searches should use full legal names, including middle initials and alternative spellings, to avoid false misses.
How to run the check
The procedure itself is straightforward. Go to the FDA's official debarment list, download the current version, and search for each investigator's full legal name. Document the date of the check, the results, and who performed it. If there is no match, the investigator is cleared. If a potential match appears, escalate to regulatory affairs for a closer look.
The FDA also maintains records of clinical investigators who have been disqualified or restricted, separate from the debarment list. Those records live in the agency's disqualification proceedings database, and sponsors should review them alongside the debarment list (FDA Clinical Investigators — Disqualification Proceedings).
Many sponsors layer additional screening on top of the FDA list. The HHS Office of Inspector General maintains the List of Excluded Individuals and Entities, which covers people and companies barred from federal health care programs (HHS OIG Exclusions). The General Services Administration's System for Award Management, sam.gov, tracks broader government-wide exclusions (SAM.gov). Commercial compliance databases add another layer. These extra checks catch risk that a single federal list might miss.
Document everything
Proper documentation is part of the requirement. Keep a log recording the date of each check, the name of the person who performed it, the database source, the search criteria, and the results. For each investigator, keep a saved copy of the search results showing no match. File this in the investigator's regulatory binder. Monitors and auditors will look for this documentation during qualification and initiation visits, so treat it as part of the site file, not an afterthought.
When a match shows up
If a debarment check returns a potential match, do not panic. Common names produce false positives. Gather additional identifying information: date of birth, professional license numbers, institutional affiliation. If the match is confirmed as the same individual, notify regulatory affairs and legal immediately. That investigator cannot serve on the study. Start the process of identifying a replacement, and document every step for the regulatory file.
Check more than once
Debarment checks are not a one-time event. The FDA list changes as new debarments are issued and old ones expire, so a person cleared at the start of a study can become debarred while it is running. Best practice is to check at multiple points across the study lifecycle: before site selection, again before site initiation, periodically during the study (at least annually), and before submitting any marketing application. Ongoing monitoring keeps the study operating with eligible investigators.
What happens if you skip it
The consequences of skipping the check are out of proportion to the effort it takes. The FDA may find data collected under a debarred investigator unreliable and exclude it from the marketing application. In extreme cases the entire submission could be rejected, costing years of development time and millions of dollars. The sponsor may face enforcement action for failing to safeguard the integrity of clinical data. And for the investigator, working while debarred is a federal offense that can lead to criminal prosecution.
Build it into your processes
The check should not depend on one person's memory. Establish a standard operating procedure that defines roles, timelines, and documentation requirements. Fold the check into the site initiation visit checklist and the regulatory document tracking system. Train clinical research associates and regulatory staff on how to perform and document it. Electronic regulatory management systems can automate periodic checks and flag expirations. Include debarment verification in vendor qualification for contract research organizations too.
The bottom line
Investigator debarment checks are a mandatory regulatory safeguard that protects trial integrity. Check the FDA debarment list before engaging any investigator, and recheck periodically throughout the study. Document every check with date, source, and results. Supplement FDA list checks with HHS OIG and sam.gov screening. If a match is found, verify identity thoroughly and escalate immediately. Never initiate a study site without confirmed clearance. These simple steps prevent regulatory and legal consequences that are far worse than any inconvenience the check causes.
This article is based on the Clarity Clinical Solutions video "Investigator Debarment Check." Watch it here: Investigator Debarment Check
References
- Clarity Clinical Solutions — "Investigator Debarment Check" (framework for this article). https://www.youtube.com/watch?v=cOOYjw6CzDI
- FDA — FDA Debarment List (Drug Product Applications); official public list of debarred individuals. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/fda-debarment-list-drug-product-applications
- FDA — Clinical Investigators: Disqualification Proceedings; records of disqualified and restricted investigators. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/clinical-investigators-disqualification-proceedings
- HHS Office of Inspector General — List of Excluded Individuals and Entities (LEIE). https://oig.hhs.gov/exclusions/
- GSA — System for Award Management (SAM.gov); government-wide exclusion screening. https://sam.gov/